Charles Schwab Investment Management Inc. Invests $3.20 Million in Septerna, Inc. (NASDAQ:SEPN)

Charles Schwab Investment Management Inc. bought a new position in shares of Septerna, Inc. (NASDAQ:SEPN) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 139,616 shares of the company’s stock, valued at approximately $3,197,000. Charles Schwab Investment Management Inc. owned about 0.31% of Septerna as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Bank of New York Mellon Corp acquired a new position in shares of Septerna during the fourth quarter worth approximately $872,000. Rhumbline Advisers purchased a new position in Septerna during the 4th quarter worth approximately $458,000. SG Americas Securities LLC purchased a new stake in Septerna in the 4th quarter worth about $185,000. Finally, New York State Common Retirement Fund purchased a new position in Septerna during the fourth quarter valued at approximately $32,000.

Septerna Stock Up 2.4 %

Shares of Septerna stock opened at $6.29 on Friday. The firm has a fifty day moving average of $10.17. Septerna, Inc. has a fifty-two week low of $4.17 and a fifty-two week high of $28.99.

Septerna (NASDAQ:SEPN) last issued its earnings results on Thursday, March 27th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.08). On average, equities research analysts expect that Septerna, Inc. will post -7.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SEPN has been the topic of several research reports. Wells Fargo & Company lowered Septerna from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $43.00 to $14.00 in a research report on Tuesday, February 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $50.00 price objective on shares of Septerna in a research note on Tuesday, February 11th.

Insiders Place Their Bets

In other news, CFO Gil M. Labrucherie bought 10,500 shares of the business’s stock in a transaction dated Wednesday, February 19th. The stock was bought at an average price of $5.51 per share, for a total transaction of $57,855.00. Following the completion of the purchase, the chief financial officer now owns 10,500 shares of the company’s stock, valued at approximately $57,855. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Alan Ezekowitz purchased 7,491 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The shares were acquired at an average cost of $6.35 per share, with a total value of $47,567.85. Following the completion of the acquisition, the director now directly owns 24,911 shares in the company, valued at approximately $158,184.85. This represents a 43.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 74,346 shares of company stock worth $439,670 over the last quarter.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.